Can I receive a bone marrow (hematopoietic stem cell) transplant from someone other than a family member? (2026 update)

Yes, it's possible. Even if no family member is a match, allogeneic transplant can be pursued through an unrelated donor or cord blood, and which path is right depends on the type of disease and how urgent treatment is.

Key summary

• Yes, it's possible. If no matching donor is found within the family, allogeneic transplant can still be arranged through an unrelated donor or cord blood.
• Donors are typically sought in the order of sibling → haploidentical (parent/child, half-match) → unrelated donor → cord blood. Korea has accumulated substantial experience with haploidentical transplants, which reduces the chance that treatment is blocked simply because no donor can be found.
• A transplant using a donor's cells is called allogeneic transplant, while one using cells collected from the patient beforehand is called autologous transplant.
• In allogeneic transplant, the donor's immune cells can attack the patient's body, causing graft-versus-host disease (GVHD), which is managed with immunosuppressants.
• Engraftment, the process by which new cells take hold, usually takes 2 to 4 weeks, during which the patient stays in a sterile isolation room.

If family members aren't a match, is there really no option left?

• No, that's not the case. Even if siblings aren't histocompatible, alternatives remain: haploidentical transplant using a parent or child, searching for an unrelated donor, or using cord blood.
• Haploidentical transplant is a method performed with tissue that is only half-matched rather than fully matched. Korea has accumulated experience with this approach, which helps broaden the pool of potential donors.
• Which path is actually feasible depends on the type of disease, the patient's age, and the urgency of treatment, so individual evaluation is necessary.

What is the step-by-step process of hematopoietic stem cell transplant?

1. Step 1: Staging tests, heart/lung/liver/kidney function tests, and infection screening are conducted over 1-2 weeks. For allogeneic transplant, the donor's tissue-typing and health checks are performed at the same time.
2. Step 2: A central venous catheter is placed for chemotherapy and transfusions.
3. Step 3: The patient undergoes about a week of high-dose chemotherapy (conditioning regimen) to clear out the diseased bone marrow.
4. Step 4: On the scheduled day, hematopoietic stem cells are infused intravenously. The infusion itself is not surgery but resembles a blood transfusion, taking only tens of minutes.
5. Step 5: The patient stays in a sterile isolation room for 2-4 weeks until engraftment is confirmed. During this period, fever, mouth sores, and low blood counts are common and are managed with transfusions and antibiotics.
6. Step 6: After engraftment is confirmed, the patient is discharged but does not return home immediately, instead staying within walking distance of the hospital for frequent outpatient visits. Hospitalization typically lasts 3-6 weeks, with a total stay of 6-8 weeks; for allogeneic transplant, close monitoring often continues until around 100 days post-transplant.

How serious is graft-versus-host disease?

• Graft-versus-host disease (GVHD), which occurs in allogeneic transplant when the donor's immune cells attack the patient's skin, gut, or liver, ranges widely from mild to severe.
• It presents as skin rash, diarrhea, elevated liver enzymes, and dryness of the eyes and mouth. It can appear acutely early on or develop into a chronic form months later.
• Because early detection and control are critical, patients are instructed to monitor for these changes daily and report them immediately. Reactivation of viral infections is also regularly checked while immunosuppressants are in use.

FAQ — If no donor can be found, does that mean treatment is impossible?

Not necessarily. Donors are searched in the order of sibling, haploidentical (parent/child), unrelated donor, and cord blood, and which path is available depends on the type of disease, age, and urgency. Korea's accumulated experience with haploidentical transplant is an option that reduces the chance of treatment being completely blocked due to lack of a donor. Exactly which path is feasible must be determined based on the patient's condition and test results.

FAQ — When can I return home after transplant?

For autologous transplant, 2-3 weeks after discharge is often the benchmark; for allogeneic transplant, it is often around 100 days post-transplant. The timing can be moved up once handover with a local hospital is arranged, with the final decision made by the medical team. It is common to prepare a handover document and video consultation so that a local hematology department can take over care after returning home.

FAQ — Is the transplant itself a major, frightening surgery?

The transplant itself is not surgery — it is closer to a blood transfusion, in which cells are infused intravenously. The difficult part is the high-dose chemotherapy (conditioning) beforehand and the recovery period until engraftment afterward, during which the patient stays in a sterile isolation room to manage infection risk.

Sources and notes

This article was written based on notes on hematopoietic stem cell transplantation (National Cancer Center Korea, NCCN patient guidelines). This content is intended to provide general medical information, and actual diagnosis, treatment methods, and outcomes may vary depending on individual conditions. Accurate diagnosis and treatment decisions should always be made in consultation with a medical professional.